S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
134 enrolled 12 charts
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Phase 2 Completed
168 enrolled 11 charts
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
Phase 2 Completed
64 enrolled 13 charts
Preoperative Treatment With Cetuximab and/or IMC-A12
Phase 2 Completed
16 enrolled 8 charts
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
Phase 2 Completed
18 enrolled 9 charts
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Phase 2 Completed
43 enrolled 12 charts
A Study in Non-Small Cell Lung Cancer
Phase 2 Completed
172 enrolled 20 charts
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
Phase 2 Completed
64 enrolled 12 charts
A Study of IMC-A12 in Advanced Solid Tumors
Phase 1 Completed
21 enrolled 16 charts
A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available
Phase 1 Completed
24 enrolled 16 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Phase 2 Completed
46 enrolled 13 charts
Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer
Phase 2 Completed
41 enrolled 14 charts
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
Phase 2 Completed
113 enrolled 13 charts
Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 1/2 Completed
48 enrolled 14 charts
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
Phase 2 Completed
65 enrolled 14 charts
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Phase 2 Completed
93 enrolled 14 charts
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Phase 2 Completed
64 enrolled 20 charts
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
Phase 2 Completed
97 enrolled 18 charts
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Phase 2 Completed
20 enrolled 12 charts
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Phase 2 Completed
175 enrolled 13 charts
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
Phase 2 Completed
29 enrolled
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Phase 1 Completed
27 enrolled
Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
Phase 1 Completed
30 enrolled
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Phase 1 Completed
21 enrolled
Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies
Phase 1 Completed
30 enrolled
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase 1 Completed
72 enrolled
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
Phase 2 Completed
178 enrolled 6 charts
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 2 Completed
116 enrolled 8 charts
Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer
Phase 2 Completed
140 enrolled 9 charts
IMC-A12 in Treating Patients With Advanced Liver Cancer
Phase 2 Completed
24 enrolled 8 charts
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 1/2 Completed
18 enrolled 6 charts
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
Phase 1 Completed
39 enrolled
A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Phase 1 Completed
18 enrolled
A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available
Phase 1 Completed
16 enrolled